Cargando…

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV

Hepatitis B- and C-virus (HBV and HCV) infections contribute to hepatocellular carcinoma (HCC) development through several different mechanisms. In addition to a diverse molecular background, HCC subtypes also show differences in their metabolic profiles, suggesting that prevention and treatment mig...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Matteis, Serena, Ghetti, Martina, Gramantieri, Laura, Marisi, Giorgia, Casadei-Gardini, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335550/ https://www.ncbi.nlm.nih.gov/pubmed/34366674 http://dx.doi.org/10.2147/OTT.S312748

Ejemplares similares

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities
por: De Matteis, Serena, et al.
Publicado: (2018)

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
por: De Matteis, Serena, et al.
Publicado: (2019)

Recent Research on Gastrointestinal Carcinoma
por: Rovesti, Giulia, et al.
Publicado: (2021)

Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV
por: Akkiz, H, et al.
Publicado: (2020)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC
por: Hiwatashi, Kiyokazu, et al.
Publicado: (2015)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs
por: Giovannini, Catia, et al.
Publicado: (2021)

The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD
por: Radmanić, Leona, et al.
Publicado: (2022)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)

Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
por: You, Maojun, et al.
Publicado: (2023)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center, West of Iran
por: Keramat, F, et al.
Publicado: (2011)

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
por: Tan, Anthony T, et al.
Publicado: (2021)

HIV, HCV and HBV: A Review of Parallels and Differences
por: Leoni, Maria C., et al.
Publicado: (2018)

Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study
por: Sarvari, Jamal, et al.
Publicado: (2013)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

HBV-Induced Immune Imbalance in the Development of HCC
por: Chen, Yongyan, et al.
Publicado: (2019)

HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection
por: Chen, Fei, et al.
Publicado: (2016)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

MicroRNAs in Animal Models of HCC
por: Fornari, Francesca, et al.
Publicado: (2019)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report
por: De Nardo, Pasquale, et al.
Publicado: (2012)

(1)H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
por: Casadei-Gardini, Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2393763dnsuba0ocgtbq9o6ikb